| abstract |
The present invention relates to the use of 1-azaxanthone-3-carboxylic acid derivatives of formula (T) and pharmaceutical compositions thereof optionally in combination with meglumine or the meglumine salt of the compound of formula (I) for treating diseases associated with tumour cells which express one or more protein of S100 family, and in treating patients that have malignancies consisting of tumours of an epithelial or mesenchymel nature such as tumours of the breast, skin, colon, lung, bladder, pancreas, esophagus, stomach or oral cavity. The invention also relates to novel meglumine salts of compounds of formula (I). |